Efavirenz

證據等級: L5

預測適應症: 3 個

Efavirenz: From HIV-1 Infection to Simian Immunodeficiency Virus Infection

One-Sentence Summary

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) widely used as a cornerstone component of combination antiretroviral therapy for HIV-1 infection in humans. The TxGNN model predicts it may be effective for Simian Immunodeficiency Virus (SIV) Infection, with 1 clinical trial (withdrawn, not directly relevant) and 16 publications—primarily non-human primate studies using RT-SHIV chimeric models—currently available as supporting evidence.

Quick Overview

Item	Content
Original Indication	HIV-1 Infection (standard NNRTI component of combination antiretroviral therapy)
Predicted New Indication	Simian Immunodeficiency Virus (SIV) Infection
TxGNN Prediction Score	99.80%
Evidence Level	L3
Canada Market Status	Not Marketed
Number of DINs	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Efavirenz inhibits HIV-1 reverse transcriptase (RT) by binding non-competitively to an allosteric pocket on the enzyme called the NNRTI binding pocket (NNIBP). This prevents RNA-to-DNA transcription and halts viral replication—a mechanism distinct from nucleoside analogues that work by competing at the active site. Because of this specificity for the HIV-1 RT structure, Efavirenz has long been a first-line treatment agent in combination regimens for HIV-1-infected adults.

SIV is the primate lentivirus most closely related to HIV and serves as a natural precursor to the human epidemic. However, wild-type SIV encodes its own RT, which differs significantly from HIV-1 RT in the NNIBP region—making native SIV largely insensitive to Efavirenz. The mechanistic rationale underpinning this prediction is therefore indirect and model-specific: researchers have created chimeric RT-SHIV viruses by replacing SIV’s RT-coding region with that of HIV-1, yielding a primate-adapted model where NNRTIs including Efavirenz are pharmacologically active. The bulk of the literature evidence supporting this prediction derives from these RT-SHIV non-human primate (NHP) experiments in rhesus and pigtail macaques.

The TxGNN knowledge graph most likely captured shared disease-node relationships between HIV-1 and SIV infection, together with documented experimental use of Efavirenz within RT-SHIV macaque models. This makes the predicted link mechanistically coherent within that narrow experimental context—but it does not extend to wild-type SIV in natural primate hosts, substantially constraining real-world translational relevance.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00863668	N/A	Withdrawn	0	Study of HIV RNA decay kinetics using Raltegravir (integrase inhibitor, not Efavirenz) in HIV-infected humans (not SIV). Withdrawn before enrolling any participants.

Important caveat: The single retrieved trial (NCT00863668) is not relevant to this repurposing hypothesis on three grounds: the study drug was Raltegravir (not Efavirenz), the disease was human HIV (not SIV), and the trial was withdrawn with zero enrollment. There are no valid clinical trials evaluating Efavirenz in SIV infection.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15328115	2004	Animal Study (NHP)	Antimicrob Agents Chemother	First characterization of Efavirenz antiviral activity in rhesus macaques infected with RT-SHIV (SIV chimera carrying HIV-1 RT); established NNRTI proof-of-concept in this primate model
15919889	2005	Animal Study (NHP)	J Virology	HAART regimen including Efavirenz 200 mg/day suppressed plasma viral RNA by >4 log in all 7 RT-SHIV-infected macaques, closely modeling human HIV treatment responses
21084490	2011	Molecular Epidemiology	J Virology	SIV/HIV-1 genetic diversity persisted in macaques across Efavirenz monotherapy and subsequent combination ART; drug-resistant variants accumulated and were documented
19889213	2009	Animal Study (NHP)	Retrovirology	Single-genome sequencing tracked RT-SHIV quasispecies dynamics in 3 pigtail macaques on Efavirenz monotherapy; documented real-time emergence and competitive dynamics of resistant clones
35856680	2022	Translational/Imaging	Antimicrob Agents Chemother	Mass spectrometry imaging of 6 ARVs (including NNRTIs) in spleens of RT-SHIV-infected NHPs; revealed spatial relationship between drug penetration, viral RNA expression, and fibrosis
22933296	2012	Virology/Molecular	J Virology	Ultrasensitive allele-specific PCR detected pre-existing NNRTI-resistant minority variants before Efavirenz initiation in RT-SHIV macaques, informing resistance emergence kinetics
15564466	2004	In Vitro	J Virology	In vitro characterization confirmed RT-SHIV sensitivity to Efavirenz depends entirely on the presence of HIV-1 RT; wild-type SIV RT was not inhibited
24777106	2014	Animal Study (NHP)	Antimicrob Agents Chemother	Four- and five-drug HAART combinations incorporating Efavirenz evaluated in RT-SHIV macaques; enhanced regimens produced faster early viral decay compared to three-drug HAART
20032180	2010	Animal Study (NHP)	J Virology	Comprehensive mapping of viral sanctuary compartments during HAART in RT-SHIV macaques; identified tissues where Efavirenz-containing regimens could not fully suppress residual replication
15040537	2004	In Vitro	Antiviral Therapy	Susceptibility panel of HIV-2, wild-type SIV (mac251, B670), and SHIV strains against 16 antiretrovirals; Efavirenz showed negligible activity against wild-type SIV strains, confirming RT structural specificity

Canada Market Information

Efavirenz currently has no registered Drug Identification Numbers (DINs) on file in Canada based on the regulatory data available for this analysis. No licensed products or approved indications are recorded.

Note: This finding warrants independent verification against the Health Canada Drug Product Database, as Efavirenz (brand name Sustiva®) has been approved in other major jurisdictions. A data retrieval gap cannot be excluded.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction linking Efavirenz to SIV infection is mechanistically plausible only within RT-SHIV chimeric animal models—where SIV is engineered to carry HIV-1 RT—and does not apply to wild-type SIV. The sole retrieved clinical trial was withdrawn and entirely irrelevant; all 16 literature citations are preclinical (NHP in vivo, in vitro, or molecular) studies. No human or veterinary clinical evidence exists, and Efavirenz’s NNRTI mechanism is inherently HIV-1 RT–specific.

To proceed, the following is needed:

Clarify the clinical target: Determine whether the intended application is (a) RT-SHIV as a research tool model, or (b) genuine treatment of SIV infection in non-human primates—these have very different feasibility profiles
Structural activity data: Commission binding assays or in silico docking of Efavirenz against wild-type SIV-RT to quantify the activity gap relative to HIV-1 RT
MOA data retrieval: Query the DrugBank API for Efavirenz’s full mechanistic profile to support formal mechanistic link analysis
Safety data gap resolution: Download and parse the Efavirenz package insert (Sustiva® or generic) to complete S1 safety screening (currently a blocking data gap)
Canada regulatory verification: Cross-check Efavirenz DIN status against the Health Canada Drug Product Database to resolve the apparent discrepancy with its known international approval status
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.